Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chlorcyclizine is a first-generation antihistamine of the phenylpiperazine (diphenylmethylpiperazine) class, primarily used to treat allergy symptoms such as rhinitis, urticaria, and pruritus. It also has antiemetic properties and can be used for symptomatic relief of hay fever and other upper respiratory allergies. In addition to its antihistaminic effects, chlorcyclizine exhibits local anesthetic, anticholinergic, and antiserotonergic activity. Its mechanism of action involves antagonism at the histamine H1 receptor (H1R) sites in peripheral tissues and the central nervous system. Chlorcyclizine is available over-the-counter in some formulations and may cause drowsiness or excitability in children[1][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chlorcyclizine.